AU2012325971B2 - Compounds and methods for enhancing innate immune responses - Google Patents
Compounds and methods for enhancing innate immune responses Download PDFInfo
- Publication number
- AU2012325971B2 AU2012325971B2 AU2012325971A AU2012325971A AU2012325971B2 AU 2012325971 B2 AU2012325971 B2 AU 2012325971B2 AU 2012325971 A AU2012325971 A AU 2012325971A AU 2012325971 A AU2012325971 A AU 2012325971A AU 2012325971 B2 AU2012325971 B2 AU 2012325971B2
- Authority
- AU
- Australia
- Prior art keywords
- group
- trifluoromethyl
- hydrogen
- imidazo
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161549784P | 2011-10-21 | 2011-10-21 | |
| US61/549,784 | 2011-10-21 | ||
| US201261692431P | 2012-08-23 | 2012-08-23 | |
| US61/692,431 | 2012-08-23 | ||
| PCT/US2012/060971 WO2013059559A2 (en) | 2011-10-21 | 2012-10-19 | Compounds and methods for enhancing innate immune responses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2012325971A1 AU2012325971A1 (en) | 2014-04-17 |
| AU2012325971B2 true AU2012325971B2 (en) | 2016-03-31 |
Family
ID=48141628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2012325971A Ceased AU2012325971B2 (en) | 2011-10-21 | 2012-10-19 | Compounds and methods for enhancing innate immune responses |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20140249143A1 (enExample) |
| EP (1) | EP2768506A4 (enExample) |
| JP (1) | JP2014532626A (enExample) |
| KR (1) | KR20140094559A (enExample) |
| CN (1) | CN103957910A (enExample) |
| AR (1) | AR088793A1 (enExample) |
| AU (1) | AU2012325971B2 (enExample) |
| BR (1) | BR112014008727A2 (enExample) |
| CA (1) | CA2851801A1 (enExample) |
| CL (1) | CL2014001016A1 (enExample) |
| CO (1) | CO6910198A2 (enExample) |
| CR (1) | CR20140175A (enExample) |
| DO (1) | DOP2014000081A (enExample) |
| EA (1) | EA201490610A1 (enExample) |
| IL (1) | IL231894A0 (enExample) |
| MX (1) | MX2014004814A (enExample) |
| PE (1) | PE20141359A1 (enExample) |
| PH (1) | PH12014500865A1 (enExample) |
| SG (2) | SG11201400988SA (enExample) |
| TW (2) | TW201333003A (enExample) |
| UY (1) | UY34406A (enExample) |
| WO (1) | WO2013059559A2 (enExample) |
| ZA (1) | ZA201402392B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103333168B (zh) * | 2013-07-23 | 2015-08-05 | 清华大学 | 一种酰胺类化合物及其制备方法与应用 |
| US9758518B2 (en) | 2015-03-04 | 2017-09-12 | Pimera, Inc. | Compositions, uses and methods for making them |
| CA2963090A1 (en) | 2014-09-29 | 2016-04-07 | The Trustees Of The University Of Pennsylvania | Antivirals against molluscum contagiosum virus |
| CN104529893B (zh) * | 2014-12-30 | 2016-08-24 | 中国科学技术大学 | 一类可以作为高尔基体细胞器探针的喹啉染料 |
| CN105175277B (zh) * | 2015-05-18 | 2018-04-03 | 中山大学肿瘤防治中心 | 一种3‑磷酸甘油醛脱氢酶的抑制剂及其制备方法和应用 |
| WO2018043747A1 (ja) * | 2016-09-05 | 2018-03-08 | 国立大学法人京都大学 | 抗ｂ型肝炎ウイルス剤 |
| JP2020512975A (ja) | 2017-03-28 | 2020-04-30 | ピメラ，インク． | Ｐｏｌ１阻害剤の新規な結晶形態 |
| US12134616B2 (en) | 2018-10-23 | 2024-11-05 | Basf Se | Tricyclic pesticidal compounds |
| CN114681472B (zh) * | 2019-03-13 | 2023-06-30 | 中国人民解放军军事科学院军事医学研究院 | 氨基葡萄糖及其衍生物作为抗病毒药物的应用 |
| EP4136086A1 (en) | 2020-04-14 | 2023-02-22 | Basf Se | Tricyclic pesticidal compounds |
| JP2023539896A (ja) * | 2020-09-03 | 2023-09-20 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | Ｓａｒｓ－ｃｏｖ－２感染を治療するためのｉｆｎａｒ２アゴニストとしてのイミダゾナフチリジンおよびイミダゾピリドピリミジン |
| WO2022175425A1 (en) | 2021-02-22 | 2022-08-25 | Glaxosmithkline Intellectual Property Development Limited | Inhaled mtor kinase inhibitors for use in the treatment or the prevention of a respiratory rna virus infection |
| US12030883B2 (en) | 2021-09-21 | 2024-07-09 | Incyte Corporation | Hetero-tricyclic compounds as inhibitors of KRAS |
| US12030884B2 (en) | 2021-10-01 | 2024-07-09 | Incyte Corporation | Pyrazoloquinoline KRAS inhibitors |
| KR20240101561A (ko) | 2021-10-14 | 2024-07-02 | 인사이트 코포레이션 | Kras의 저해제로서의 퀴놀린 화합물 |
| WO2023244672A1 (en) | 2022-06-14 | 2023-12-21 | Assembly Biosciences, Inc. | 2-(imidazo[1, 2-a]1,8-naphthyridin-8-yl)-1,3,4-oxadiazole derivatives as enhancers of innate immune response for the treatment of viral infections |
| WO2024215912A1 (en) * | 2023-04-14 | 2024-10-17 | Humanwell Pharmacuetical Us | Monoacylglycerol lipase (magl) inhibitors for the treatment of pain and related medical disorders |
| JPWO2025089372A1 (enExample) * | 2023-10-26 | 2025-05-01 | ||
| WO2025128898A1 (en) | 2023-12-13 | 2025-06-19 | Assembly Biosciences, Inc. | Imidazo[1,2-a][1,8]naphthyridine derivatives as enhancers of innate immune response for the treatment of viral infections |
| WO2026084958A1 (en) | 2024-10-14 | 2026-04-23 | Assembly Biosciences, Inc. | Tricyclic heteroaryl compounds useful for enhancing innate immune responses |
| WO2026084957A1 (en) | 2024-10-14 | 2026-04-23 | Assembly Biosciences, Inc. | Tricyclic heteroaryl compounds useful for enhancing innate immune responses |
| WO2026084955A1 (en) | 2024-10-14 | 2026-04-23 | Assembly Biosciences, Inc. | Tricyclic heteroaryl compounds useful for enhancing innate immune responses |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE441449B (sv) * | 1979-02-09 | 1985-10-07 | Roussel Uclaf | Heterocykliska derivat och farmaceutiska kompositioner innehallande dessa derivat |
| US4492697A (en) * | 1983-08-16 | 1985-01-08 | Ayerst, Mckenna & Harrison, Inc. | 4H-Imidazo[2,3-c]pyrido[2,3-e][1,4]oxazine derivatives |
| US6110929A (en) * | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| RU2310657C2 (ru) * | 2002-04-03 | 2007-11-20 | Ф.Хоффманн-Ля Рош Аг | Имидазоконденсированные соединения и фармацевтическая композиция, содержащая их |
| US8592368B2 (en) * | 2003-12-19 | 2013-11-26 | University Of South Florida | JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection |
| DE102005019181A1 (de) * | 2005-04-25 | 2006-10-26 | Novartis Ag | Peptid-Deformylase (PDF) Inhibitoren 1 |
| CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| JP5481671B2 (ja) * | 2009-03-31 | 2014-04-23 | ダイキン工業株式会社 | 高分子アクチュエータ素子用電極膜及びそれを有する高分子アクチュエータ素子 |
| GB0919432D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| GB201002409D0 (en) * | 2010-02-12 | 2010-03-31 | Univ Nottingham | Methods |
-
2012
- 2012-10-19 SG SG11201400988SA patent/SG11201400988SA/en unknown
- 2012-10-19 PE PE2014000559A patent/PE20141359A1/es not_active Application Discontinuation
- 2012-10-19 EA EA201490610A patent/EA201490610A1/ru unknown
- 2012-10-19 EP EP12840986.9A patent/EP2768506A4/en not_active Withdrawn
- 2012-10-19 AU AU2012325971A patent/AU2012325971B2/en not_active Ceased
- 2012-10-19 CA CA2851801A patent/CA2851801A1/en not_active Abandoned
- 2012-10-19 PH PH1/2014/500865A patent/PH12014500865A1/en unknown
- 2012-10-19 MX MX2014004814A patent/MX2014004814A/es unknown
- 2012-10-19 KR KR1020147013668A patent/KR20140094559A/ko not_active Withdrawn
- 2012-10-19 BR BR112014008727A patent/BR112014008727A2/pt not_active IP Right Cessation
- 2012-10-19 CN CN201280051347.8A patent/CN103957910A/zh active Pending
- 2012-10-19 JP JP2014537274A patent/JP2014532626A/ja active Pending
- 2012-10-19 WO PCT/US2012/060971 patent/WO2013059559A2/en not_active Ceased
- 2012-10-19 SG SG10201505664WA patent/SG10201505664WA/en unknown
- 2012-10-19 US US14/353,067 patent/US20140249143A1/en not_active Abandoned
- 2012-10-22 TW TW101138997A patent/TW201333003A/zh unknown
- 2012-10-22 TW TW104126180A patent/TW201542567A/zh unknown
- 2012-10-22 UY UY0001034406A patent/UY34406A/es not_active Application Discontinuation
- 2012-10-22 AR ARP120103945A patent/AR088793A1/es unknown
-
2014
- 2014-03-18 CO CO14058151A patent/CO6910198A2/es unknown
- 2014-03-31 ZA ZA2014/02392A patent/ZA201402392B/en unknown
- 2014-04-03 IL IL231894A patent/IL231894A0/en unknown
- 2014-04-21 CR CR20140175A patent/CR20140175A/es unknown
- 2014-04-21 CL CL2014001016A patent/CL2014001016A1/es unknown
- 2014-04-21 DO DO2014000081A patent/DOP2014000081A/es unknown
Non-Patent Citations (1)
| Title |
|---|
| D1 : GUEIFFIER el al."Synthesis, Structure and Reactivity ot Imidazo[1,2-a](1.B]naphthyridines" J.Heterocyclic Chem., 34, 765 (1997). * |
Also Published As
| Publication number | Publication date |
|---|---|
| UY34406A (es) | 2013-05-31 |
| TW201333003A (zh) | 2013-08-16 |
| PH12014500865A1 (en) | 2014-05-26 |
| IL231894A0 (en) | 2014-05-28 |
| JP2014532626A (ja) | 2014-12-08 |
| AR088793A1 (es) | 2014-07-10 |
| TW201542567A (zh) | 2015-11-16 |
| KR20140094559A (ko) | 2014-07-30 |
| BR112014008727A2 (pt) | 2017-04-25 |
| EA201490610A1 (ru) | 2014-09-30 |
| CO6910198A2 (es) | 2014-03-31 |
| WO2013059559A2 (en) | 2013-04-25 |
| CA2851801A1 (en) | 2013-04-25 |
| CL2014001016A1 (es) | 2015-01-16 |
| DOP2014000081A (es) | 2014-07-15 |
| ZA201402392B (en) | 2017-09-27 |
| SG10201505664WA (en) | 2015-09-29 |
| WO2013059559A3 (en) | 2013-11-14 |
| EP2768506A4 (en) | 2015-08-19 |
| AU2012325971A1 (en) | 2014-04-17 |
| US20140249143A1 (en) | 2014-09-04 |
| MX2014004814A (es) | 2014-05-27 |
| CR20140175A (es) | 2014-06-03 |
| SG11201400988SA (en) | 2014-07-30 |
| EP2768506A2 (en) | 2014-08-27 |
| PE20141359A1 (es) | 2014-10-13 |
| CN103957910A (zh) | 2014-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012325971A1 (en) | Compounds and methods for enhancing innate immune responses | |
| JP5882329B2 (ja) | ＤＮＡ−ＰＫ阻害剤としてのイミダゾ［４，５−ｃ］キノリン | |
| AU2012314498B2 (en) | Viral replication inhibitors | |
| JP4970048B2 (ja) | イミダゾ［４，５−ｃ］ピリジン化合物および抗ウイルス治療の方法 | |
| AU2010252007B2 (en) | (Dihydro) imidazoiso [5, 1-a] quinolines as FSH receptor agonists for the treatment of fertility disorders | |
| AU2011258465B2 (en) | Bicyclic heteroaryl kinase inhibitors and methods of use | |
| CN103534254B (zh) | 作为抗肿瘤剂的三环和四环吡唑并[3,4-b]吡啶化合物 | |
| IL268013B1 (en) | Tetrahydropyrazolopyrimidine compounds | |
| JP5411393B2 (ja) | ピラゾロキノリン類 | |
| AU2006332000A1 (en) | Substituted imidazoquinolines, imidazonaphthyridines, and imidazopyridines, compositions, and methods | |
| WO2018183586A1 (en) | Inhibitors of kinase networks and uses thereof | |
| AU2005293821B2 (en) | N,N'-dithenylurea derivatives used in the form of kinase inhibitors | |
| CN107074880A (zh) | 二氢吡啶并吡嗪‑1,8‑二酮和它们在治疗、改善或预防病毒疾病中的用途 | |
| JP2022547815A (ja) | アザヘテロアリール化合物及びその使用 | |
| AU2008259534A1 (en) | Triazolo [1, 5-a] quinolines as adenosine A3 receptor ligands | |
| KR20150074007A (ko) | 3,4-이치환된 1h-피라졸 및 4,5-이치환된 티아졸 syk 억제제 | |
| AU2005297531B2 (en) | Phenylurea derivatives used as inhibitors of tyrosinkinase for treating tumors | |
| US8071587B2 (en) | (Dihydro)imidazoiso[5,1-A]quinolines | |
| CN101538267B (zh) | 咪唑并[4,5-c]吡啶化合物和抗病毒治疗的方法 | |
| WO2025128898A1 (en) | Imidazo[1,2-a][1,8]naphthyridine derivatives as enhancers of innate immune response for the treatment of viral infections | |
| WO2026097054A1 (en) | Isoquinoline dmpk binders | |
| WO2024254599A1 (en) | Hpgd inhibitors and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |